ALSO NOTED: FDA studies blindness; Roche gets OK for HIV drug; FDA approves Zemplar; and much more...

> The FDA is examining a handful of cases in which men taking Viagra have gone blind. The agency says that there is currently no known link, but that it will investigate. Story

> Roche has received European marketing approval for 500 mg formulation of the HIV drug Invirase. Story

> The FDA has approved Abbott's Zemplar (paricalcitol) for the prevention and treatment of secondary hyperparathyroidism. Release

> The FDA has approved Novartis Pharmaceuticals' extended release form of Focalin for ADHD, which is licensed from Celgene. Story

> Ariad has begun its first clinical trial of oral AP23573 in patients with relapsed or refractory cancers. Release

> NovaDel Pharma of Flemington, New Jersey, raised $7 million in a private placement. Release

> Santarus has filed an NDA for Zegerid chewable tablets. Release

> King Pharmaceuticals and Astellas have filed suit against several generic drug makers following their ANDA for Adenoscan, a pharmacologic stress agent. Release

And Finally... A group of scientists is challenging new research claiming that people who are slightly overweight live longer. Story

Suggested Articles

The FDA rejected the new drug application for golodirsen, the follow-up to Exondys 51, Sarepta’s first treatment for Duchenne muscular dystrophy.

Levi Garraway is set to take up one of the biggest hot seats in biopharma when he becomes the next chief medical officer at Roche.

Vanda Pharmaceuticals received a Complete Response Letter from the FDA taking issue with a small study testing Hetlioz in jet lag disorder.